
Name of the Issue: Entero Healthcare Solutions Limited**Last Updated on:****31-May-26**

1 Type of Issue Initial Public Offer**2 Issue Size (Rs. Mn)** 16,000.00
- Fresh Issue Size (Rs. Millions) 10,000.00
- Offer for Sale Component (Rs. Millions) 6,000.00**Source: Prospectus dated February 13, 2024*

3 Grade of issue along with name of the rating agency**Name** NA
Grade NA**4 Subscription Level (Number of times)** 1.32*** Figure is prior to rejections**Source: Basis of allotment ad dated February 15, 2024*

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) On Allotment **	24.95%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (March 31, 2024)^	25.58%
(iii) at the end of 1st FY (March 31, 2024)^	25.58%
(iv) at the end of 2nd FY (March 31, 2025)^	29.56%
(v) at the end of 3rd FY (March 31, 2026)^	20.18%

***Basis of Allotment**^Holding of institutions category as disclosed to Stock Exchanges*

6 Financials of the issuer

Parameters	<i>(Rs. Million)</i>		
	1st FY (March 31,2024)	2nd FY (March 31,2025)	3rd FY (March 31,2026)
Income from operations	3,182	4,087	65,912
Net Profit for the period	384	192	1,150
Paid-up equity share capital	435	435	435
Reserves excluding revaluation reserves	15,829	16,069	16,451

7 Trading Status

The equity shares of Entero Healthcare Solutions Limited were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on February 16, 2024

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2026)	Frequently Traded

Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	None	None
(ii) at the end of 2nd FY (March 31, 2025)#	Mr. Kevin Rohitbhai Daftary Mr. Vipul Indravadan	Appointed Resigned
(iii) at the end of 3rd FY (March 31, 2026)	Nil	Nil

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

(Rs. In Millions)

Particulars	Estimated utilisation from Net Proceeds	Estimated schedule of deployment of Net		
		2024	2025	2026
		(Rs. In millions)		
Repayment or prepayment of certain borrowings, in full or part availed by our Company	1,425.00	1,425.00	-	-
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	4,800.00	1,500.00	2,500.00	800.00
Pursuing inorganic growth initiatives through acquisitions*	2,370.00	600.00	1,770.00	-
General corporate purposes*	917.00	93.00	480.00	344.00
Total	9,512.00	3,618.00	4,750.00	1,144.00

*Source: Prospectus

*The amount to be utilised for general corporate purposes and inorganic growth initiatives does not individually exceed 25% of the Gross Proceeds respectively and does not exceed 35% collectively of the Gross Proceeds from the Fresh Issue, in accordance with Regulation 7(3) of the SEBI ICDR Regulations.

(ii) Actual utilization

(Rs. In Millions)

Particulars	Amount proposed to be funded from Net Proceeds	Amount utilised at the end of Quarter (Feb 26)	Unutilised amount	Comments from Monitoring Agency
Repayment or prepayment of certain borrowings, in full or part availed by our Company	1,425.00	1,425.00	Nil	No comments
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	4,800.00	4,800.00	-	No comments
Pursuing inorganic growth initiatives through acquisitions	2,370.00	2,370.00	-	No comments
General corporate purposes	953.00	953.00	-	Revision in GCP is on account of actual offer related expenses being lower by INR 3.60 crore
Total	9,548.00	9,548.00	0	

*Revised cost

Source - As per monitoring agency report dated February 12, 2026

(iii) Reasons for deviation, if any

Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds

NA

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document*

Revision in GCP is on account of actual offer expenditure being lower than estimated by INR 0.13 Crs.

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

NA

*Source - As per monitoring agency report dated February 12, 2026

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	1,258.00
Listing Date	16-Feb-24

Price parameters	At close of listing day (February 16, 2024)	Close of 30th calendar day from listing day (March 16, 2024) ⁽¹⁾	Close of 90th calendar day from listing day (May 15, 2024) ⁽²⁾	As at the end of the 1st FY after the listing of the issue (31st March, 2024) ⁽³⁾		
				Closing price	High (During the FY)	Low (During the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	1,258.00	1,010.85	1,008.45	1,003.15	1,258.00	974.45
S & P BSE SENSEX ⁽⁵⁾	72,426.64	72,643.43	72,987.0	73,651.4	74,190.3	73,120.3
Sectoral Index ⁽⁶⁾	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025)* ⁽³⁾			As at the end of the 3rd FY after the listing of the issue (31st March, 2026)* ⁽³⁾⁽⁴⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price on Designated Stock Exchange ⁽⁵⁾	1,136.55	1,155.10	1,126.05	1,245.9	1,258.2	1,208.8
S & P BSE SENSEX ⁽⁵⁾	77,414.92	77,766.70	77,185.62	71,947.6	73,165.32	71,774.13
Sectoral Index ⁽⁶⁾	NA	NA	NA	NA	NA	NA

* Being index of BSE, the designated stock exchange

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.

(6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio	As disclosed in offer document*	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)	At the end of 3rd FY (March 31, 2026)	
EPS (Basic)	Company Consolidated	-3.43	10.81	21.80	26.44
	Peer Group				
	MedPlus Health Services Limited (basic/diluted)	4.17/4.17	5.48	12.57	18.33
	Industry Avg	NA	NA	NA	NA
P/E	Company Consolidated	NA	92.80	52.14	47.19
	Peer Group				
	MedPlus Health Services Limited (basic/diluted)	177.21	126.78	60.43	45.80
	Industry Avg	NA	NA	NA	NA
RoNW	Company Consolidated	-1.86%	2.43%	6.23%	6.81%
	Peer Group				
	MedPlus Health Services Limited (basic/diluted)	3.36%	4.16%	8.63%	11.12%
	Industry Avg	NA	NA	NA	NA
NAV per share	Company Consolidated	174.21	376.62	396.28	815.62
	Peer Group	NA	NA	NA	NA
	MedPlus Health Services Limited (basic/diluted)	124.93	132.00	145.36	164.54
	Industry Avg	NA	NA	NA	NA

Notes

* Sourced from Prospectus dated February 13, 2024

14 Any other material information

Date	Announcement
16-Feb-24	Entero Healthcare Solutions Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
19-Feb-24	Entero Healthcare Solutions Limited has informed the Exchange about Closure of Trading Window
20-Feb-24	Entero Healthcare Solutions Limited has informed the Exchange regarding 'The contact details of the Key Managerial Personnel (KMP) of the Company pursuant to Regulation 30(5) of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015'
25-Feb-24	Entero Healthcare Solutions Limited has informed the Exchange regarding temporary suspension of drug license of CPD Pharma Private Limited (CPD), a wholly owned subsidiary of the Company, for a period of seven days from 26.02.2024 to 03.03.2024
28-Feb-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange about Board Meeting to be held on 08-Mar-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business.
05-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Intimation of Earnings call on financial results for the Quarter and Nine Months ended December 31, 2023
08-Mar-24	Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended December 31, 2023.
08-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on March 08, 2024.

08-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Acquisition
08-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Investor Presentation
09-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Copy of Newspaper Publication dated March 09, 2024
09-Mar-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange regarding Acquisition
11-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Change in Auditors of the company.
11-Mar-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
11-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Link of Recording of Earnings Call held on March 11, 2024
15-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange about Transcript
27-Mar-24	Entero Healthcare Solutions Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
27-Mar-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange about Closure of Trading Window
05-Apr-24	Disclosure in compliance with SEBI Circular No. SEBI/HO/CFD/CMDI/CIR/2019/140 dated November 21, 2019, of default on payment of interest/ repayment of principal amount on loans from Bank(s)/ financial institutions and unlisted debt
10-Apr-24	Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2024.
10-Apr-24	OrbiMed Asia III Mauritius Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
12-Apr-24	Prabhat Agrawal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
06-May-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on May 06, 2024.
06-May-24	Entero Healthcare Solutions Limited has informed the Exchange about Acquisition of 80% paidup equity share capital of Avenir Lifecare Pharma Private Limited (ALPPL)
06-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange regarding Acquisition
15-May-24	Report of Monitoring Agency issued by ICRA Limited for the quarter ended March 31, 2024
22-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 .
24-May-24	Entero Healthcare Solutions Limited has informed the Exchange about Schedule of Earnings call on audited financial results for the Quarter and Year ended March 31, 2024.
29-May-24	Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
29-May-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Board meeting held on May 29, 2024.
29-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
29-May-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Corrigendum to outcome of Board Meeting dated May 29, 2024
29-May-24	Entero Healthcare Solutions Limited has informed the Exchange about Investor Presentation
30-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange regarding Acquisition
30-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange regarding Acquisition
30-May-24	ENTERO HEALTHCARE SOLUTIONS LIMITED has informed the Exchange regarding Acquisition
31-May-24	Entero Healthcare Solutions Limited has informed the Exchange about Copy of Newspaper Publication
31-May-24	Entero Healthcare Solutions Limited has informed the Exchange regarding Corrigendum to the Investor Presentation on the audited financial results of the Company for the quarter and year ended March 31, 2024.
04-Jun-24	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
06-Jun-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27-Jun-24	Closure of Trading Window
28-Jun-24	Board Meeting Outcome for Outcome Of Board Meeting Held On June 28, 2024
28-Jun-24	Announcement under Regulation 30 (LODR)-Acquisition
23-Jul-24	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
02-Aug-24	Board Meeting Outcome for Outcome Of Board Meeting Held On August 02, 2024
02-Aug-24	Announcement under Regulation 30 (LODR)-Acquisition
02-Aug-24	Notice Of 06Th Annual General Meeting Of The Company Scheduled To Be Held On Wednesday, August 28, 2024 At 11:30
03-Aug-24	Reg. 34 (1) Annual Report
03-Aug-24	Business Responsibility and Sustainability Reporting (BRSR)
03-Aug-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Aug-24	Corrigendum To The Notice Of 06Th Annual General Meeting
06-Aug-24	Announcement under Regulation 30 (LODR)-Newspaper Publication
08-Aug-24	Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2024
08-Aug-24	Statement Of Deviation Or Variation In Utilization Of Funds Raised Under Initial Public Offering - Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015
08-Aug-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14-Aug-24	Unaudited Financial Results For The Quarter Ended June 30, 2024
14-Aug-24	Board Meeting Outcome for Outcome Of Board Meeting Held On August 14, 2024
14-Aug-24	Announcement under Regulation 30 (LODR)-Acquisition
15-Aug-24	Announcement under Regulation 30 (LODR)-Investor Presentation
22-Aug-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
28-Aug-24	Shareholder Meeting / Postal Ballot-Outcome of AGM Adoption of Financials Appointment of Directors Sumona Chakraborty (liable to retire by rotation) Appointment of M/s. M S K A & Associates, Chartered Accountants as Statutory Auditors of the Company for a period of 5 years Appointment of Mr. Kevin Rohitbhai Daftary (DIN:10637792) as Non Executive Non Independent Director of the Company Approval for increase in limits to provide loan, guarantee or security in respect of loan made to any person or body corporate or to make investment in any other body corporate under Section 186 of the Companies Act, 2013 Ratification of Approval of the 'Entero Employee Stock Option Plan, 2023' ("ESOP 2023"/ "Plan") Ratification of the extension of the benefits under the Entero Employee Stock Option Plan, 2023' ("ESOP 2023"/ "PLAN") to the employees of subsidiary companies of the Company Alteration of the Articles of Association of the Company and insertion of clauses pursuant to Regulation 31B of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
28-Aug-24	Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
10-Sep-24	Intimation regarding Credit Rating under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
27-Sep-24	Closure of Trading Window
06-Nov-24	Board Meeting Intimation for Consideration, Approval And Take On Record The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.
12-Nov-24	Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2024
12-Nov-24	Intimation for acquisition of M/s. Radha Swami Medico House, proprietorship firm.
12-Nov-24	Acquisition of M/s. Shree Enterprises, Partnership Firm.
13-Nov-24	Statement Of Deviation Or Variation For The Quarter Ended September 30, 2024
13-Nov-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report

14-Nov-24	Announcement under Regulation 30 (LODR)-Newspaper Publication where Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024
19-Nov-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript to discuss the Company's Financial results for the Quarter and Half year ended September 30, 2024
09-Dec-24	Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
10-Dec-24	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23-Dec-24	Closure of Trading Window
02-Jan-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation for Investor meeting to be held on January 07, 2025
02-Jan-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation for Investor meeting to be held on January 09, 2025
02-Jan-25	Change Of Name Of Registrar And Share Transfer Agent ("RTA") Of The Company
10-Jan-25	Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 for Invesco Mutual Fund
16-Jan-25	Appointment of Company Secretary and Compliance Officer
16-Jan-25	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
16-Jan-25	Disclosure under Regulation 30A of LODR-Change in Authorization of Key Managerial Personnel for determining materiality of an event or information
25-Jan-25	Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 for SMALLCAP World Fund, Inc.
31-Jan-25	Intimation Regarding Receipt Of Listing And Trading Approval For 13,940 Equity Shares From The BSE Limited ("BSE") And National Stock Exchange Of India Limited ("NSE")
03-Feb-25	Board Meeting Intimation for Approval And Take On Record The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Nine-Months Ended December 31, 2024.
08-Feb-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation of Earnings call on Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2024.
12-Feb-25	Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2024
12-Feb-25	Board Meeting Outcome for Outcome Of Board Meeting Held On February 12, 2025 to consider and approve The Unaudited Financial Results (Standalone and Consolidated) and Limited Review Report of the Statutory Auditors for the Quarter and Nine Months ended December 31, 2024
12-Feb-25	Integrated Filing (Financials) for the quarter ended December 31, 2024
12-Feb-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
12-Feb-25	Statement Of Deviation For The Quarter Ended December 31, 2024
12-Feb-25	Announcement under Regulation 30 (LODR)-Investor Presentation on Unaudited Financial Results for the quarter and nine months ended December 31, 2024
13-Feb-25	Announcement under Regulation 30 (LODR)-Newspaper Publication where Unaudited Financial Results for the Quarter and Nine-Months ended December 31, 2024
13-Feb-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Recording of Earnings Call/ Conference Call
13-Feb-25	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation of Schedule of Analyst / Institutional
17-Feb-25	Intimation of Schedule of Analyst / Institutional Investor meeting to be held on February 21, 2025
18-Feb-25	Intimation of cancellation of Analyst/ Institutional Investor Meeting scheduled on February 21, 2025
19-Feb-25	Intimation under regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 - Transcript of Earning Call
20-Feb-25	Intimation of Schedule of Analyst / Institutional Investor meeting to be held on February 27, 2025
21-Feb-25	Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 with respect to receipt of GST demand order by Subsidiary Company.
27-02-2025	Intimation of Schedule of Analyst / Institutional Investor meeting to be held on March 05, 2025
05-03-2025	Intimation of Schedule of Analyst / Institutional Investor meeting to be held on March 11, 2025
06-03-2025	Update on investment in equity shares of Getwell Medicare Solution Private Limited ("Subsidiary") issued on Rights Basis
19-Mar-25	Submission of information pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015- Media Release/Press Release.
19-Mar-25	Intimation of Schedule of Analyst / Institutional Investor meeting to be held on March 26, 2025
21-Mar-25	Outcome of Board Meeting held on March 21, 2025
21-Mar-25	Resignation and appointment of Chief Financial Officer
24-Mar-25	Intimation of Closure of Trading Window from April 01, 2025 upto 48 hours after the declaration of Financial Results of the Company for the quarter and year ended March 31, 2025
28-Mar-25	Update on intimation on acquisition of balance equity shares in Getwell Medicare Solution Private Limited to make it wholly owned subsidiary Company
09-Apr-25	Certificate under Regulation 74(5) of SEBI (Depositories and Participant) Regulation, 2018 for the quarter ended March 31, 2025.
09-May-25	Submission of Monitoring Agency Report for the quarter ended March 31, 2025
21-May-25	Entero Healthcare Solutions Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025, inter alia, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2025.
22-May-25	Submission of Resignation letter- Mr. Vipul Indravadan Desai
23-May-25	Intimation of Earnings call on Audited Financial Results of the Company for the Quarter and Year ended March 31, 2025
27-May-25	Outcome of Board meeting held on May 27, 2025 inter-alia for approval of financial results for quarter and year ended March 31, 2025.
27-May-25	Submission of Audited Financial results for quarter and year ended March 31, 2025
27-May-25	Change in authorization of Key Managerial Personnel ("KMP") for determining materiality of an event or information
27-May-25	Intimation regarding proposed acquisitions.
27-May-25	Allotment of 1200 Equity shares of Rs. 10/- each to the eligible employees of the Company, upon exercise of options vested under the Entero Employee Stock Option Plan 2023.
27-May-25	Appointment of Secretarial Auditor of the Company.
27-May-25	Change In Designation Of Mr. Kevin Daftary From Non Executive Non Independent Director To Nominee Director
27-May-25	Investor presentation on Audited Financial Results of the Company for the quarter and year ended March 31, 2025.
28-May-25	Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Recording of Earnings Call/ Conference Call
29-May-25	Submission of Newspaper for publication of Audited Financial Results for the quarter and year ended March 31, 2025
29-May-25	Submission of Annual Secretarial Compliance Report for the year ended March 31, 2025
18-Jun-25	Board Meeting Outcome- Day, date and time of the 7th Annual General Meeting, appointment of scrutinizer, Updated "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information", grant of fresh 5900 (Five Thousand Nine Hundred) Employee Stock Options under the existing "Entero Employee Stock Option Plan 2023
18-Jun-25	Intimation for grant of 5900 Options pursuant to "Entero Employees Stock Options Plan 2023" to the eligible employees of the Company
18-Jun-25	Intimation for Code of Practices and Procedure for fair disclosure of UPSI
25-Jun-25	Intimation of closure of Trading Window
25-Jul-25	Board Meeting Intimation for Approval And Take On Record The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2025
08-08-2025	Board Meeting Outcome- Unaudited Financial Results For The Quarter Ended June 30, 2025
08-Aug-25	Monitoring Agency Report-quarter ended June 30, 2025

25-Aug-25	Submission of Annual Report of the Company for the FY 2024-25.
25-Aug-25	Submission Of Notice Of 7Th Annual General Meeting Scheduled To Be Held On September 18, 2025
25-Aug-25	Submission of Business Responsibility and Sustainability Report for the FY 2024-25
03-Sep-25	Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
18-Sep-25	Shareholder Meeting / Postal Ballot-Outcome of AGM a. receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2025, together with the Reports of the Board of Directors and the Auditors thereon; b. receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2025, together with the Report of the Auditors thereon; c. To appoint a director in place of Mr. Prem Sethi (DIN: 07077034), who retires by rotation and being eligible, offers himself for re-appointment; d. Appointment of Secretarial Auditors
18-Sep-25	Appointment of M/s. BNP & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company
29-Sep-25	Outcome of Board meeting dated September 29, 2025
29-Sep-25	Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition and Divestment sale of entire stake (100%) in Suprabhat Pharmaceutical Private Limited ("Suprabhat"), a wholly owned subsidiary of the Company; execute Share Purchase Agreement ("SPA"), for acquiring 60% stake in Ace Cardiopathy Solutions Private Limited ("Ace Cardiopathy")
29-Sep-25	Board Meeting Intimation for Approval Of The Financial Results For The Quarter Ended September 30, 2025
12-Nov-25	Board Meeting Outcome for Outcome Of Board Meeting Dated November 12, 2025
12-Nov-25	Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025
12-Nov-25	Allotment of Equity Shares pursuant to exercise of ESOP under Employee Stock Option Scheme 2023
12-Nov-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
12-Nov-25	Change in designation of Mr. Abhitesh Kumar from President- Retail Business and New Initiatives to Chief Growth Officer of the Company
12-Nov-25	Announcement under Regulation 30 (LODR)-Acquisition a. execution of definitive agreements for acquiring 80 % stake in Bioaide Technologies Private Limited directly; b. e Board has approved, inter-alia, entering into a binding Memorandum of Understanding for acquiring 51% stake in Anand Chemiceutics Private Limited
04-Dec-25	Affirmation of Credit Rating by India Ratings and Research
06-Dec-25	Intimation For Grant Of 73060Options Pursuant To "Entero Employees Stock Options Plan 2023" To The Eligible Employees Of The Company
15-Jan-26	Change Of Name Of M/S. M S K A & Associates, Chartered Accountants, Statutory Auditor Of The Company - Upon Conversion Of Firm Into LLP
27-Jan-26	Disclosure Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015-Temporary Suspension of Drug licenses of Atreja Healthcare Solutions Private Limited, a wholly owned subsidiary of the Company, for a period of three days from 30.01.2026 to 01.02.2026
03-Feb-26	Board Meeting Intimation for Approval Of The Financial Results For The Quarter Ended December 31, 2025
07-Feb-26	Update under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Company has completed acquisition of majority equity stake (51.51%) in Anand Chemiceutics Private Limited.
12-Feb-26	Board Meeting Outcome- Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025
12-Feb-26	Intimation For Grant Of Fresh 5,000 ESOP
12-Feb-26	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
06-May-26	Confirmation order sanctioning the Scheme of Amalgamation
18-May-26	Entero Healthcare Solutions Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve and take on record the Audited Standalone and Consolidated Financial Results/Statements of the Company for the quarter and year ended March 31, 2026
25-May-26	Board Meeting Outcome- Adoption of financials for FY 26
25-May-26	The Board has approved allotment of 7,240 (Seven Thousand Two Hundred Forty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employees of the Company, upon exercise of the Options vested in them under the Entero Employee Stock Option Plan 2023
25-May-26	Acquisition of Vishal Surgicals and Vishal Surgicals & Medicals, a Partnership Firm, through its subsidiary company Sai Pharma Distributors Private Limited through Slump Sale / Business Transfer Agreement (BTA)
25-May-26	the Board approved the re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092), Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Director of the Company for the second term of five years w.e.f. August 25, 2026, to August 24, 2031, subject to the approval of the shareholders in the ensuing Annual General Meeting
25-May-26	The Grant Of Fresh 7,300 (Seven Thousand Three Hundred) Employee Stock Options Under The Existing 'Entero Employee Stock Option Plan 2023
25-May-26	The Board Approved The Re-Appointment Of Internal Auditor M/S. Ernst & Young LLP (EY) For The Next Financial Year 2026-27
25-May-26	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
27-May-26	Annual Secretarial Compliance Report for the financial year ended March 31, 2026

Source: www.bseindia.com

Notes:

The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.